A) Distributions of BROCA HRD status and B) RAD51 HRD and the best objective responses to niraparib and pembrolizumab. C) The number (nSNVs) per megabite (MB) compared in WGS, Oncopanel and a panel sequencing data. D) ROC curve showing sensitivity versus false positive rate determined using OncoPanel simulations from WGS data from ICGC (https://dcc.icgc.org/releases). The true positives and true negatives are determined based on presence of Signature 3 in WGS ovarian cancer data from ICGC consortium. The blue part of the ROC curve indicates SigMA scores below the strict threshold and the red part of the ROC curve indicates SigMA scores above the strict threshold corresponding to 2% false positive rate, and a sensitivity of 65%. E) Comparison of SigMA score for OncoPanel data from TOPACIO trial and OncoPanel simulations from WGS data showing that the simulations describe data well. F) (Left) Distribution of SigMA score in Sig3+ and Sig3-WGS samples, where Sig3 status is determined by a standard NMF based signature analysis from WGS data. (Right) Distribution of SigMA score in Sig3+ and Sig3-samples defined based on whether the SigMA score is above or below the strict threshold. G) Same as panel (c) but showing the total number of SNVs in four groups. H) (Top) The density of aggregated mutations from Sig3+ (Left) and Sig-(Right) samples in WGS data based on NMF based signature analysis (Middle) Same as the distributions on the top but for simulated OncoPanels that are classified into Sig3+ and Sig3-groups based on the SigMA score (Bottom) Same as the distributions in the middle but for OncoPanel data. On the right of each mutational spectra a bar graph shows the fraction of mutational signature exposures in each distribution, the colors indicate different signatures and Sig3 is shown in orange. Box plots are presented as the range (whiskers), center line as the median, and the bounds of box mark the highest and lowest quartiles. Number of samples is show in parenthesis.
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Chemo exposed n=30
Median 4.3 months (range 1.5 -91.1) 
Chemo naïve n=30
Supplementary Figure 2 Chemotherapy exposure affects Nanostring gene expression analysis
A) The pre-trial samples were collected either at diagnosis (chemo-naïve, n=30), during clinical treatment (chemo-exposed, n=30), or as pre-trial biopsies (n=2). B) In the samples available for Nanostring analysis, the chemo-exposure affected the gene expressions; the mean differences of the pathway scores between chemo-naïve (n=23) compared to chemo-exposed (n=22) are shown as dots, and lines represent the 95%CI. Pathways higher in chemo-naïve are displayed in red and pathways higher in chemo-exposed in blue (Mann-Whitney-U test; r = effect size). C) Chemo-exposed samples had higher z-scores for many of the immune cell types (black box). D) Chemo-exposure status significantly associated with PD-L1 immunohistohemistry (IHC) positivity measured as Complete Proportion Score ≥1 (Fisher's exact test) . E) In chemo-naïve samples, all patients who responded were positive for interferon score as assigned by having the pathway score in the highest quartile of the range (≥75%) for any of the three Type-I interferon pathways (i.e. interferon score) (Fisher's exact test). All test were two-sided. No adjustment was made for multiple hypothesis testing (see materials and methods). Box plots are presented as the range (whiskers), center line as the median, bounds of box mark the highest and lowest quartiles, and the dashed line represents the mean. 
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Supplementary Figure 3 Cell-type proportions in the tumor microenvironment
A) The chemo-exposed samples had lower proportion of tumor cells (Mann-Whitney-U), B) higher proportion of stromal (Mann-Whitney-U) and C) higher proportion of immune cells (Mann-Whitney-U) compared to the chemo-naïve samples. D) The chemo-exposed samples also had higher proportion of antigen presenting cells (Mann-Whitney-U), and E) neutrophils (Mann-Whitney-U) compared to chemo naïve samples. F) Heatmap of unsupervised hierarchical clustering of the proportions of immune cell subpopulations of the total immune cells (columns) and samples (rows) annotated by Sig3, Immune score, sample category and confirmed best objective response (BOR). All test were two-sided. No adjustment was made for multiple hypothesis testing. R= effect size. Box plots are presented as the range (whiskers), center line as the median, bounds of box mark the highest and lowest quartiles, and the dashed line represents the mean. 
